🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

16 results for “Suzhou” Clear

  1. Bilateral Nucleus Accumbens DBS (Suzhou Sceneray)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Obsessive Compulsive Disorder

    phase 3 other terminated

    1 trial

  2. Lurasidone

    Sumitomo Pharma (Suzhou) Co.,

    Bipolar I Depression

    phase 3 small molecule completed

    1 trial

  3. Napabucasin

    Sumitomo Pharma (Suzhou) Co.,

    Carcinoma, Pancreatic Ductal

    phase 3 small molecule completed

    1 trial

  4. Placebo

    Sumitomo Pharma (Suzhou) Co.,

    Bipolar Depression

    phase 3 small molecule completed

    1 trial

  5. SHR-A2009 ; Aumolertinib

    Suzhou Ribo Life Science Co.

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  6. Solriamfetol

    Ignis Therapeutics (Suzhou) Limited

    Sleep Apnea, Obstructive

    phase 3 small molecule completed

    1 trial

  7. Suzhou Sceneray® DBS System

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Opiate Addiction

    phase 3 other active

    1 trial

  8. Alkotinib Capsules

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    ALK-positive Non-small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  9. BBI608

    Sumitomo Pharma (Suzhou) Co.,

    Malignant Pleural Mesothelioma

    phase 2 small molecule completed

    1 trial

  10. IBI3016

    Innovent Biologics (Suzhou) Co.

    Hypertension

    phase 2 small molecule active

    2 trials

  11. ZG005

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    Biliary Tract Carcinoma

    phase 2 small molecule active

    1 trial

  12. Dose escalation of SA030

    Suzhou Ribo Life Science Co.

    Obese

    phase 1 small molecule active

    1 trial

  13. RBD7022

    Suzhou Ribo Life Science Co.

    Hyperlipemia

    phase 1 small molecule completed

    1 trial

  14. UTAA91 injection

    Suzhou Ribo Life Science Co.

    Rheumatoid Arthritis (RA)

    phase 1 mab active

    1 trial

  15. ZG0895 Hydrochloride for Injection

    Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  16. placebo

    Innovent Biologics (Suzhou) Co.

    Healthy

    phase 1 mab completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources